XAF 5

Drug Profile

XAF 5

Alternative Names: XAF-5; XOPH5

Latest Information Update: 14 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harvard Medical School
  • Developer Allergan
  • Class Small molecules
  • Mechanism of Action Adipocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Subcutaneous fat disorders

Most Recent Events

  • 21 Apr 2016 Topokine Therapeutics has been acquired and merged into Allergan
  • 26 Feb 2016 Topokine Therapeutics suspends enrolment in a phase IIa trial for Subcutaneous fat disorders (excess submental fat) in USA (NCT01990326)
  • 01 Jan 2016 Phase-II/III clinical trials in Subcutaneous fat disorders (lower lid steatoblepharon in adults and the elderly) in USA (Topical, ointment) (NCT02607683)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top